Non Interventional Post Marketing Programme in Neuroendocrine Tumours

Inclusion Criteria: * The patient must give written (personally signed and dated) informed consent for their data to be included in the database for this Post Marketing Surveillance programme and any subsequent analysis. * The patient must have been receiving treatment with Somatuline Autogel at a stable dose for at least 4 months. * The patient must have a diagnosis of neuroendocrine tumours * The patient must be at least 18 years of age * For patients receiving or intending to receive Somatuline Autogel by home injection: * The patient must be able to store Somatuline Autogel safely in a refrigerator in their own home and either collect it from their GP/Pharmacy on a monthly basis, or receive the medication by a home delivery service. Exclusion Criteria: * The patient is pregnant or breast-feeding, unless continued treatment with Somatuline Autogel is clearly needed (as determined by the treating clinician).